FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2766677984> ?p ?o ?g. }

• W2766677984 endingPage "1940" @default.
• W2766677984 startingPage "1930" @default.
• W2766677984 abstract "Epidemiologic studies suggest that higher serum phosphaturic hormone fibroblast growth factor 23 levels are associated with increase morbidity and mortality. The aim of the FGF23 Reduction Efficacy of a New Phosphate Binder in CKD Trial was to evaluate the effect of sevelamer carbonate on serum C-terminal fibroblast growth factor 23 levels in normophosphatemic patients with CKD stage 3b/4.Patients with CKD, eGFR between 45 and 15 ml/min per 1.73 m2, fasting serum phosphate concentration >3.1 mg/dl, and serum C-terminal fibroblast growth factor 23 >80 relative units/ml were included in our double-blind, placebo-controlled, randomized multicenter study. All patients received 100,000 IU cholecalciferol at time of randomization. Participants received either placebo or sevelamer carbonate 4.8 g daily during a 12-week period. Biologic parameters, including serum C-terminal fibroblast growth factor 23, intact fibroblast growth factor 23, and α-klotho, were evaluated at baseline and 12 weeks after inclusion.Of 96 screened patients, 78 (mean±SD age: 63±13 years old; 70% men; mean eGFR: 27±9 ml/min per 1.73 m2) met the inclusion criteria. At baseline, mean eGFR was 27±9 ml/min per 1.73 m2, mean serum phosphate level was 3.8±0.5 mg/dl, and median (interquartile range) serum C-terminal fibroblast growth factor 23 level was 157 (120-241) relative units/ml. After 12 weeks of treatment, urinary phosphate-to-creatinine ratio fell significantly in the sevelamer group. The sevelamer and placebo groups did not differ significantly in terms of median change in serum C-terminal fibroblast growth factor 23 levels: the median (interquartile range) change was 38 (-13-114) relative units/ml in the placebo group and 37 (-1-101) relative units/ml in the sevelamer group (P=0.77). There was no significant difference in serum intact fibroblast growth factor 23, α-klotho, or phosphate levels changes between the two groups. Serum total and LDL cholesterol levels fell significantly in the sevelamer group.In our double-blind, placebo-controlled, randomized study performed in normophosphatemic patients with CKD, a 12-week course of sevelamer carbonate significantly reduced phosphaturia without changing serum phosphorus but did not significantly modify serum C-terminal fibroblast growth factor 23 and intact fibroblast growth factor 23 or α-klotho levels." @default.
• W2766677984 created "2017-11-10" @default.
• W2766677984 creator A5001665060 @default.
• W2766677984 creator A5003490861 @default.
• W2766677984 creator A5004453256 @default.
• W2766677984 creator A5005480103 @default.
• W2766677984 creator A5010505148 @default.
• W2766677984 creator A5011863891 @default.
• W2766677984 creator A5032149927 @default.
• W2766677984 creator A5033170314 @default.
• W2766677984 creator A5037287050 @default.
• W2766677984 creator A5044141185 @default.
• W2766677984 creator A5057090299 @default.
• W2766677984 creator A5066434139 @default.
• W2766677984 creator A5084509236 @default.
• W2766677984 date "2017-10-26" @default.
• W2766677984 modified "2023-10-02" @default.
• W2766677984 title "Randomized Clinical Trial of Sevelamer Carbonate on Serum Klotho and Fibroblast Growth Factor 23 in CKD" @default.
• W2766677984 cites W1561791332 @default.
• W2766677984 cites W1562538838 @default.
• W2766677984 cites W1973733126 @default.
• W2766677984 cites W1977645780 @default.
• W2766677984 cites W1997203483 @default.
• W2766677984 cites W2011871493 @default.
• W2766677984 cites W2013706974 @default.
• W2766677984 cites W2015915623 @default.
• W2766677984 cites W2025200180 @default.
• W2766677984 cites W2049898087 @default.
• W2766677984 cites W2052419320 @default.
• W2766677984 cites W2071966346 @default.
• W2766677984 cites W2077315258 @default.
• W2766677984 cites W2090458713 @default.
• W2766677984 cites W2091948921 @default.
• W2766677984 cites W2092823666 @default.
• W2766677984 cites W2094551185 @default.
• W2766677984 cites W2095948376 @default.
• W2766677984 cites W2098122721 @default.
• W2766677984 cites W2102734552 @default.
• W2766677984 cites W2107420262 @default.
• W2766677984 cites W2114360920 @default.
• W2766677984 cites W2120129493 @default.
• W2766677984 cites W2128473811 @default.
• W2766677984 cites W2138484848 @default.
• W2766677984 cites W2141675473 @default.
• W2766677984 cites W2143729965 @default.
• W2766677984 cites W2149030597 @default.
• W2766677984 cites W2152171089 @default.
• W2766677984 cites W2153481494 @default.
• W2766677984 cites W2163181937 @default.
• W2766677984 cites W2171425889 @default.
• W2766677984 cites W2274190170 @default.
• W2766677984 cites W2320786490 @default.
• W2766677984 cites W2470464816 @default.
• W2766677984 doi "https://doi.org/10.2215/cjn.03030317" @default.
• W2766677984 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5718266" @default.
• W2766677984 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29074818" @default.
• W2766677984 hasPublicationYear "2017" @default.
• W2766677984 type Work @default.
• W2766677984 sameAs 2766677984 @default.
• W2766677984 citedByCount "35" @default.
• W2766677984 countsByYear W27666779842017 @default.
• W2766677984 countsByYear W27666779842018 @default.
• W2766677984 countsByYear W27666779842019 @default.
• W2766677984 countsByYear W27666779842020 @default.
• W2766677984 countsByYear W27666779842021 @default.
• W2766677984 countsByYear W27666779842022 @default.
• W2766677984 countsByYear W27666779842023 @default.
• W2766677984 crossrefType "journal-article" @default.
• W2766677984 hasAuthorship W2766677984A5001665060 @default.
• W2766677984 hasAuthorship W2766677984A5003490861 @default.
• W2766677984 hasAuthorship W2766677984A5004453256 @default.
• W2766677984 hasAuthorship W2766677984A5005480103 @default.
• W2766677984 hasAuthorship W2766677984A5010505148 @default.
• W2766677984 hasAuthorship W2766677984A5011863891 @default.
• W2766677984 hasAuthorship W2766677984A5032149927 @default.
• W2766677984 hasAuthorship W2766677984A5033170314 @default.
• W2766677984 hasAuthorship W2766677984A5037287050 @default.
• W2766677984 hasAuthorship W2766677984A5044141185 @default.
• W2766677984 hasAuthorship W2766677984A5057090299 @default.
• W2766677984 hasAuthorship W2766677984A5066434139 @default.
• W2766677984 hasAuthorship W2766677984A5084509236 @default.
• W2766677984 hasBestOaLocation W27666779841 @default.
• W2766677984 hasConcept C114276007 @default.
• W2766677984 hasConcept C119060515 @default.
• W2766677984 hasConcept C126322002 @default.
• W2766677984 hasConcept C126894567 @default.
• W2766677984 hasConcept C134018914 @default.
• W2766677984 hasConcept C142724271 @default.
• W2766677984 hasConcept C159641895 @default.
• W2766677984 hasConcept C168563851 @default.
• W2766677984 hasConcept C204243189 @default.
• W2766677984 hasConcept C204787440 @default.
• W2766677984 hasConcept C27081682 @default.
• W2766677984 hasConcept C2776036575 @default.
• W2766677984 hasConcept C2777425297 @default.
• W2766677984 hasConcept C2778653478 @default.
• W2766677984 hasConcept C2779148903 @default.
• W2766677984 hasConcept C2780306776 @default.

• next